Elena Rodriguez-Vieitez

List of Publications by Year
in descending order

38 papers	1,826 citations	471477 17 h-index	501174 28 g-index
42 all docs	42 docs citations	42 times ranked	2697 citing authors

#	Article	IF	Citations
1	Age, sex and APOE-Îµ4 modify the balance between soluble and fibrillar Î²-amyloid in non-demented individuals: topographical patterns across two independent cohorts. Molecular Psychiatry, 2022, 27, 2010-2018.	7.9	9
2	Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-Î² positivity. Molecular Psychiatry, 2021, 26, 5864-5874.	7.9	22
3	Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 612-622.	6.4	16
4	Altered perivascular fibroblast activity precedes ALS disease onset. Nature Medicine, 2021, 27, 640-646.	30.7	69
5	Astrocyte Biomarkers in Alzheimer Disease. Neurology, 2021, 96, .	1.1	70
6	Association of cortical microstructure with amyloid-Î² and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. Molecular Psychiatry, 2021, 26, 7813-7822.	7.9	17
7	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 84, 103-117.	2.6	4
8	PET Imaging of Monoamine Oxidase B. , 2021, , 521-545.		4
9	Plasma sTREM2: a potential marker of cerebrovascular injury in neurodegenerative disorders. Brain, 2021, 144, 3283-3285.	7.6	5
10	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
11	The relationship between cortical microstructural changes and in vivo amyloidâ€Î²Â² and tau in aging and preclinical Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041626.	0.8	0
12	Towards harmonizing subtyping methods for PET and MRI studies of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042807.	0.8	2
13	Comparison of subtyping methods for neuroimaging studies in Alzheimerâ€™s disease: a call for harmonization. Brain Communications, 2020, 2, fcaa192.	3.3	24
14	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Neurology, 2020, 94, e2026-e2036.	1.1	42
15	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2831-2847.	6.4	45
16	Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes. Neurobiology of Aging, 2019, 82, 40-47.	3.1	7
17	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1369-1382.	6.4	74
18	S2â€01â€02: PET MARKERS OF ASTROCYTES. Alzheimer's and Dementia, 2019, 15, P514.	0.8	0

#	Article	IF	Citations
19	Tau PET imaging in neurodegenerative tauopathiesâ€”still a challenge. Molecular Psychiatry, 2019, 24, 1112-1134.	7.9	409
20	Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 348-356.	6.4	41
21	Tau positron emission tomography imaging in tauopathies: The added hurdle of offâ€target binding. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 232-236.	2.4	86
22	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. , 2018, 14, 652-663.		18
23	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimer's Research and Therapy, 2018, 10, 45.	6.2	11
24	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. Methods in Molecular Biology, 2018, 1750, 231-251.	0.9	18
25	Comparability of [¹⁸F]THK5317 and [¹¹C]PIB blood flow proxy images with [¹⁸F]FDG positron emission tomography in Alzheimerâ€™s disease. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 740-749.	4.3	46
26	Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimerâ€™s Disease. Journal of the International Neuropsychological Society, 2017, 23, 195-203.	1.8	18
27	Tau PET imaging: present and future directions. Molecular Neurodegeneration, 2017, 12, 19.	10.8	220
28	[P4â€“533]: GENOTYPEâ€DEPENDENT LONGITUDINAL TRAJECTORIES OF COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1554.	0.8	0
29	P4â€349: EARLYâ€PHASE [11C]PIB PET is Comparable to [18F]FDG PET as a Marker of Disease Progression in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P1171.	0.8	0
30	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 922-936.	7.6	235
31	Comparison of Early-Phase ¹¹C-Deuterium-l-Deprenyl and ¹¹C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 1071-1077.	5.0	63
32	IC-P-126: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P86-P86.		0
33	O1-02-03: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P127-P127.		0
34	Early astrocytosis in autosomal dominant Alzheimerâ€™s disease measured in vivo by multi-tracer positron emission tomography. Scientific Reports, 2015, 5, 16404.	3.3	110
35	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. Journal of Alzheimer's Disease, 2015, 47, 661-667.	2.6	14
36	Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1119-1132.	6.4	121

#	Article	IF	Citations
37	IC-03-03: COMPARISON OF MEASUREMENTS OF CEREBRAL BLOOD FLOW BY EARLY FRAMES OF 11C-DEUTERIUM-L-DEPRENYL (11C-DED) AND 11C-PIB PET TRACERS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE. , 2014, 10, P7-P7.		1
38	P3-214: COMPARISON OF MEASUREMENTS OF CEREBRAL BLOOD FLOW BY EARLY FRAMES OF 11C-DEUTERIUM-L-DEPRENYL (11C-DED) AND 11C-PIB PET TRACERS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE. , 2014, 10, P709-P709.		0